Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 8
2006 5
2007 4
2008 3
2010 1
2011 2
2012 1
2013 5
2014 6
2015 6
2016 8
2017 6
2018 2
2019 4
2020 6
2021 10
2022 7
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for alexander roesch
Search for Alexander Remesch instead (1 results)
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Schadendorf D, et al. Among authors: roesch a. Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Lancet. 2018. PMID: 30238891 Review.
Melanoma.
Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Schadendorf D, et al. Among authors: roesch a. Nat Rev Dis Primers. 2015 Apr 23;1:15003. doi: 10.1038/nrdp.2015.3. Nat Rev Dis Primers. 2015. PMID: 27188223 Review.
Melanoma stem cells.
Roesch A. Roesch A. J Dtsch Dermatol Ges. 2015 Feb;13(2):118-24. doi: 10.1111/ddg.12584. J Dtsch Dermatol Ges. 2015. PMID: 25631128 Review. English, German.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group. Livingstone E, et al. Among authors: roesch a. Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099927 Clinical Trial.
Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma.
Picard D, Felsberg J, Langini M, Stachura P, Qin N, Macas J, Reiss Y, Bartl J, Selt F, Sigaud R, Meyer FD, Stefanski A, Stühler K, Roque L, Roque R, Pandyra AA, Brozou T, Knobbe-Thomsen C, Plate KH, Roesch A, Milde T, Reifenberger G, Leprivier G, Faria CC, Remke M. Picard D, et al. Among authors: roesch a. Acta Neuropathol. 2023 Oct;146(4):551-564. doi: 10.1007/s00401-023-02626-5. Epub 2023 Sep 1. Acta Neuropathol. 2023. PMID: 37656187 Free PMC article.
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: roesch a. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
MCU controls melanoma progression through a redox-controlled phenotype switch.
Stejerean-Todoran I, Zimmermann K, Gibhardt CS, Vultur A, Ickes C, Shannan B, Bonilla Del Rio Z, Wölling A, Cappello S, Sung HM, Shumanska M, Zhang X, Nanadikar M, Latif MU, Wittek A, Lange F, Waters A, Brafford P, Wilting J, Urlaub H, Katschinski DM, Rehling P, Lenz C, Jakobs S, Ellenrieder V, Roesch A, Schön MP, Herlyn M, Stanisz H, Bogeski I. Stejerean-Todoran I, et al. Among authors: roesch a. EMBO Rep. 2022 Nov 7;23(11):e54746. doi: 10.15252/embr.202254746. Epub 2022 Sep 26. EMBO Rep. 2022. PMID: 36156348 Free PMC article.
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM, Kimmig M, Griewank K, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Welzel J, Engel DR, Kreft S, Sucker A, Lodde G, Krefting F, Stoffels I, Klode J, Roesch A, Zimmer L, Livingstone E, Hadaschik E, Becker JC, Weichenthal M, Tasdogan A, Schadendorf D, Ugurel S. Placke JM, et al. Among authors: roesch a. EBioMedicine. 2023 Oct;96:104774. doi: 10.1016/j.ebiom.2023.104774. Epub 2023 Sep 4. EBioMedicine. 2023. PMID: 37660535 Free PMC article.
94 results